본문 바로가기
KERD
논문KCI 등재

Optimizing Helicobacter pylori Treatment: An Updated Review of Empirical and Susceptibility Test-Based Treatments

Suzuki Sho|Ishibashi Fumiaki|Nagai Mizuki|Mochida Kentaro|Morishita Tetsuo
거트앤리버 소화기연관학회협의회|2023.09|Gut and Liver|제17권 제5호|pp. 684-697|DOI 10.5009/gnl220429

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

AntibioticsDrug resistanceHelicobacter pyloriBacterial susceptibility testVonoprazan

초록

As the rate of discovery of drug-resistant Helicobacter pylori cases increases worldwide, the relevant societies have updated their guidelines for primary eradication regimens. A promising strategy against drug-resistant H. pylori is tailored therapy based on the results of an antibiotic susceptibility test; however, it is difficult to apply this strategy to all cases. Although culture-based antibiotic susceptibility tests can assess resistance to any antimicrobial agent, their greatest disadvantage is the time required to draw a conclusion. In contrast, molecular-based methods, such as polymerase chain reaction, can rapidly determine the presence of resistance, although a single test can only test for one type of antimicrobial agent. Additionally, the limited availability of facilities for molecular-based methods has hindered their widespread use. Therefore, low-cost, minimally invasive, simple, and effective primary regimens are needed. Several studies have compared the efficacy of the latest primary eradication regimens against that of tailored therapies, and their results have shaped guidelines. This article reviews the latest research on empirical and tailored treatments for H. pylori infections. Evidence for the superiority of tailored therapy over empirical therapy is still limited and varies by region and treatment regimen. A network meta-analysis comparing different empirical treatment regimens showed that vonoprazan triple therapy provides a superior eradication effect. Recently, favorable results towards vonoprazan dual therapy have been reported, as it reached eradication levels similar to those of vonoprazan triple therapy. Both vonoprazan dual therapy and tailored therapy based on antibiotic susceptibility tests could contribute to future treatment strategies.

Abstract

As the rate of discovery of drug-resistant Helicobacter pylori cases increases worldwide, the relevant societies have updated their guidelines for primary eradication regimens. A promising strategy against drug-resistant H. pylori is tailored therapy based on the results of an antibiotic susceptibility test; however, it is difficult to apply this strategy to all cases. Although culture-based antibiotic susceptibility tests can assess resistance to any antimicrobial agent, their greatest disadvantage is the time required to draw a conclusion. In contrast, molecular-based methods, such as polymerase chain reaction, can rapidly determine the presence of resistance, although a single test can only test for one type of antimicrobial agent. Additionally, the limited availability of facilities for molecular-based methods has hindered their widespread use. Therefore, low-cost, minimally invasive, simple, and effective primary regimens are needed. Several studies have compared the efficacy of the latest primary eradication regimens against that of tailored therapies, and their results have shaped guidelines. This article reviews the latest research on empirical and tailored treatments for H. pylori infections. Evidence for the superiority of tailored therapy over empirical therapy is still limited and varies by region and treatment regimen. A network meta-analysis comparing different empirical treatment regimens showed that vonoprazan triple therapy provides a superior eradication effect. Recently, favorable results towards vonoprazan dual therapy have been reported, as it reached eradication levels similar to those of vonoprazan triple therapy. Both vonoprazan dual therapy and tailored therapy based on antibiotic susceptibility tests could contribute to future treatment strategies.

참고문헌 (133)

  1. Fukase K, "Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer : an open-label, randomized controlled trial", Lancet, 372, pp.392~397 (2008)
  2. Uemura N, "Helicobacter py-lori infection and the development of gastric cancer", N Engl J Med, 345, pp.784~789 (2001)
  3. Jiro Watari, "Preventing Metachronous Gastric Cancer after the Endoscopic Resection of Gastric Epithelial Neoplasia: Roles of Helicobacter pylori Eradication and Aspirin", Gut and Liver, 14(3), pp.281~290 (2020), 거트앤리버 소화기연관학회협의회[DOI]
  4. Kakiuchi T, "A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture : a preliminary report", J Gastroenterol, 54, pp.699~707 (2019)
  5. Kusano C, "The administrative project of Helicobacter pylori infection screening among junior high school students in an area of Japan with a high incidence of gastric cancer", Gastric Cancer, 20(Suppl 1), pp.16~19 (2017)
  6. Sekiguchi M, "Epidemiological trends and future perspectives of gastric cancer in Eastern Asia", Digestion, 103, pp.22~28 (2022)
  7. Thung I, "Review article : the global emergence of Helicobacter pylori antibiotic resistance", Aliment Pharmacol Ther, 43, pp.514~533 (2016)
  8. Suzuki S, "The ideal Helicobacter pylori treatment for the present and the future", Digestion, 103, pp.62~68 (2022)
  9. Suzuki S, "Development of Helicobacter pylori treatment : how do we manage antimicrobial resistance?", World J Gastroenterol, 25, pp.1907~1912 (2019)
  10. Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht VI", Florence consensus report, 2022, pp.71, 1724~1762
  11. Yuan Y, "Optimum duration of regimens for Helicobacter pylori eradication", Cochrane Database Syst Rev, (12), pp.CD008337~ (2013)
  12. Fallone CA, "Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada", Can J Gastroenterol, 27, pp.397~402 (2013)
  13. Fallone CA, "The Toronto consensus for the treatment of Helicobacter pylori infection in adults", Gastroenterology, 151, pp.51~69 (2016)
  14. Shiota S, "Antibiotic resistance of Helicobacter pylori among male United States veterans", Clin Gastroenterol Hepatol, 13, pp.1616~1624 (2015)
  15. McMahon BJ, "The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections", Ann Intern Med, 139, pp.463~469 (2003)
  16. Megraud F, "Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption", Gut, 62, pp.34~42 (2013)
  17. Lim SG, "The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use", Dig Liver Dis, 48, pp.385~390 (2016)
  18. Chey WD, "ACG Clinical Guideline : treatment of Helicobacter pylori infection", Am J Gastroenterol, 112, pp.212~239 (2017)
  19. Liu WZ, "Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection", Helicobacter, 23, pp.e12475~ (2018)
  20. Kato M, "Guidelines for the management of Helicobacter pylori infection in Japan : 2016 revised edition", Helicobacter, 24, pp.e12597~ (2019)
  21. Hye-Kyung Jung, "Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020", The Korean Journal of Internal Medicine, 36(4), pp.807~838 (2021), 대한내과학회[DOI]
  22. Jenkins H, "Randomised clinical trial : safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438(vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects", Aliment Pharmacol Ther, 41, pp.636~648 (2015)
  23. Sakurai Y, "Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects : a randomised open-label cross-over study", Aliment Pharmacol Ther, 42, pp.719~730 (2015)
  24. Kagami T, "Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype", Aliment Pharmacol Ther, 43, pp.1048~1059 (2016)
  25. Sugimoto M, "Role of vonoprazan in Helicobacter pylori eradication therapy in Japan", Front Pharmacol, 9, pp.1560~ (2019)
  26. Murakami K, "Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication : a phase III, randomised, double-blind study", Gut, 65, pp.1439~1446 (2016)
  27. Maruyama M, "Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication : a randomized controlled trial", Can J Gastroenterol Hepatol, 2017, pp.4385161~ (2017)
  28. Noda H, "A novel potassiumcompetitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori", J Gastrointestin Liver Dis, 25, pp.283~288 (2016)
  29. Yang C, "Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication : a meta-analysis of randomized clinical trials", J Clin Pharm Ther, 47, pp.897~904 (2022)
  30. Ang D, "Clinical trial : seven-day vonoprazan-versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication", Aliment Pharmacol Ther, 56, pp.436~449 (2022)
  31. Bunchorntavakul C, "Randomized clinical trial : 7-day vonoprazan-based versus 14-day omeprazolebased triple therapy for Helicobacter pylori", J Gastroenterol Hepatol, 36, pp.3308~3313 (2021)
  32. Shin WG, "Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use : nationwide survey", Helicobacter, 21, pp.266~278 (2016)
  33. 김범진, "Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis", Journal of Korean Medical Science, 31(8), pp.1246~1253 (2016), 대한의학회
  34. Jung Hye-Kyung, "Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020", Gut and Liver, 15(2), pp.168~195 (2021), 거트앤리버 소화기연관학회협의회[DOI]
  35. Choi Yoon Jin, "Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial", Gut and Liver, 16(4), pp.535~546 (2022), 거트앤리버 소화기연관학회협의회[DOI]
  36. Han Sungpil, "Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study", Gut and Liver, 17(1), pp.92~99 (2023), 거트앤리버 소화기연관학회협의회[DOI]
  37. Lee Jung Won, "Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori", Gut and Liver, 15(1), pp.53~60 (2021), 거트앤리버 소화기연관학회협의회[DOI]
  38. Lee Jin, "Role of Tegoprazan in Helicobacter pylori Eradication Therapy", Gut and Liver, 16(4), pp.493~494 (2022), 거트앤리버 소화기연관학회협의회[DOI]
  39. Jung YS, "7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection : real-world evidence", J Gastroenterol Hepatol, 37, pp.1911~1918 (2022)
  40. Tshibangu-Kabamba E, "Helicobacter pylori infection and antibiotic resistance : from biology to clinical implications", Nat Rev Gastroenterol Hepatol, 18, pp.613~629 (2021)
  41. Luther J, "Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection : systematic review and meta-analysis of efficacy and tolerability", Am J Gastroenterol, 105, pp.65~73 (2010)
  42. Gerrits MM, "Helicobacter pylori and antimicrobial resistance : molecular mechanisms and clinical implications", Lancet Infect Dis, 6, pp.699~709 (2006)
  43. Xia HX, "Clarithromycin resistance in Helicobacter pylori : prevalence in untreated dyspeptic patients and stability in vitro", J Antimicrob Chemother, 37, pp.473~481 (1996)
  44. Liou JM, "The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors : a nationwide study", PLoS One, 10, pp.e0124199~ (2015)
  45. Kim Sung Eun, "Management of Helicobacter pylori Infection: A Comparison between Korea and the United States", Gut and Liver, 16(4), pp.503~514 (2022), 거트앤리버 소화기연관학회협의회[DOI]
  46. Kuo YT, "Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 2, pp.707~715 (2017)
  47. Savoldi A, "Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions", Gastroenterology, 155, pp.1372~1382 (2018)
  48. Bujanda L, "Antibiotic resistance prevalence and trends in patients infected with Helicobacter pylori in the period 2013-2020: results of the European registry on H. pylori management (Hp-EuReg)", Antibiotics(Basel), 10, pp.1058~ (2021)
  49. Boyanova L, "Multidrug resistance in Helicobacter pylori : current state and future directions", Expert Rev Clin Pharmacol, 12, pp.909~915 (2019)
  50. Kouitcheu Mabeku LB, "Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates", BMC Infect Dis, 19, pp.880~ (2019)
  51. Shokrzadeh L, "Prevalence of multiple drug-resistant Helicobacter pylori strains among patients with different gastric disorders in Iran", Microb Drug Resist, 21, pp.105~110 (2015)
  52. Lyu T, "High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in southern China : a municipality-wide, multicentre, prospective cohort study", J Antimicrob Chemother, 75, pp.3391~3394 (2020)
  53. Park JY, "The prevalence of multidrug resistance of Helicobacter pylori and its impact on eradication in Korea from 2017 to 2019: a singlecenter study", Antibiotics(Basel), 9, pp.646~ (2020)
  54. Olano M, "Diagnostic performance of the culture and susceptibility of Helicobacter pylori in peruvian patients : results from a sentinel laboratory", Rev Peru Med Exp Salud Publica, 38, pp.406~411 (2021)
  55. The Editors, "Hetero-resistance : an under-recognised confounder in diagnosis and therapy?", J Med Microbiol, 50, pp.1018~1020 (2001)
  56. Kouhsari E, "Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection : a systematic review and metaanalysis", Ann Clin Microbiol Antimicrob, 21, pp.19~ (2022)
  57. Rizvanov AA, "Helicobacter pylori and its antibiotic heteroresistance : a neglected issue in published guidelines", Front Microbiol, 10, pp.1796~ (2019)
  58. Ye L, "Using next-generation sequencing to analyze Helicobacter pylori clones with different levofloxacin resistances from a patient with eradication failure", Medicine(Baltimore), 99, pp.e20761~ (2020)
  59. Sukri A, "The emergence of multidrugresistant Helicobacter pylori in Southeast Asia: a systematic review on the trends and intervention strategies using antimicrobial peptides", Antibiotics(Basel), 10, pp.1061~ (2021)
  60. Osato MS, "Antimicrobial susceptibility testing for Helicobacter pylori : sensitivity test results and their clinical relevance", Curr Pharm Des, 6, pp.1545~1555 (2000)
  61. Valdivieso-García A, "Cost analysis and antimicrobial susceptibility testing comparing the E test and the agar dilution method in Campylobacter jejuni and Campylobacter coli", Diagn Microbiol Infect Dis, 65, pp.168~174 (2009)
  62. Osato MS, "Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States", Arch Intern Med, 161, pp.1217~1220 (2001)
  63. Tang X, "Re-assessment of the disk diffusion technique for routine antimicrobial susceptibility testing for Helicobacter pylori", Helicobacter, 25, pp.e12703~ (2020)
  64. Weseler A, "A novel colorimetric broth microdilution method to determine the minimum inhibitory concentration(MIC)of antibiotics and essential oils against Helicobacter pylori", Pharmazie, 60, pp.498~502 (2005)
  65. Oleastro M, "Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori", J Clin Microbiol, 41, pp.397~402 (2003)
  66. Glocker E, "Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach", J Clin Microbiol, 42, pp.2241~2246 (2004)
  67. Woo HY, "Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens", Helicobacter, 14, pp.22~28 (2009)
  68. Binmaeil H, "Development and validation of multiplex quantitative PCR assay for detection of Helicobacter pylori and mutations conferring resistance to clarithromycin and levofloxacin in gastric biopsy", Infect Drug Resist, 14, pp.4129~4145 (2021)
  69. Yilmaz O, "Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy", World J Gastroenterol, 13, pp.671~675 (2007)
  70. Booka M, "Polymerase chain reaction : restriction fragment length polymorphism analysis of clarithromycin-resistant Helicobacter pylori infection in children using stool sample", Helicobacter, 10, pp.205~213 (2005)
  71. Umegaki N, "Clarithromycin-resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Japan", J Gastroenterol Hepatol, 15, pp.906~909 (2000)
  72. Vécsei A, "Stool polymerase chain reaction for Helicobacter pylori detection and clarithromycin susceptibility testing in children", Clin Gastroenterol Hepatol, 8, pp.309~312 (2010)
  73. Kawai T, "Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities", J Gastroenterol Hepatol, 23(Suppl 2), pp.S171~S174 (2008)
  74. Arslan N, "Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection", World J Gastroenterol, 23, pp.2854~2869 (2017)
  75. Mégraud F, "Resistance of Helicobacter pylori to antibiotics", Aliment Pharmacol Ther, 11(Suppl 1), pp.43~53 (1997)
  76. Zanotti G, "Structural aspects of Helicobacter pylori antibiotic resistance", Adv Exp Med Biol, 1149, pp.227~241 (2019)
  77. Saruuljavkhlan Batsaikhan, "Benefits of a Molecular-Based Method for the Detection of Clarithromycin-Resistant Helicobacter pylori", Gut and Liver, 15(4), pp.487~489 (2021), 거트앤리버 소화기연관학회협의회[DOI]
  78. Hussein RA, "Detection of clarithromycin resistance and 23SrRNA point mutations in clinical isolates of Helicobacter pylori isolates : phenotypic and molecular methods", Saudi J Biol Sci, 29, pp.513~520 (2022)
  79. Noh Jin Hee, "Real-Time Polymerase Chain Reaction for the Detection of Helicobacter pylori and Clarithromycin Resistance", Gut and Liver, 17(3), pp.375~381 (2023), 거트앤리버 소화기연관학회협의회[DOI]
  80. Hu Y, "Helicobacter pylori and antibiotic resistance, a continuing and intractable problem", Helicobacter, 21, pp.349~363 (2016)
  81. Cattoir V, "Update on fluoroquinolone resistance in Helicobacter pylori : new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility", Int J Antimicrob Agents, 29, pp.389~396 (2007)
  82. Nishizawa T, "Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR", J Clin Microbiol, 45, pp.303~305 (2007)
  83. Cambau E, "Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori", J Clin Microbiol, 47, pp.3600~3607 (2009)
  84. Lee JW, "GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea", Scand J Gastroenterol, 49, pp.1058~1067 (2014)
  85. Pohl D, "Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing", World J Gastroenterol, 25, pp.4629~4660 (2019)
  86. Chen J, "Application of next-generation sequencing to characterize novel mutations in clarithromycinsusceptible Helicobacter pylori strains with A2143G of 23S rRNA gene", Ann Clin Microbiol Antimicrob, 17, pp.10~ (2018)
  87. Iwamoto A, "Whole-genome sequencing of clarithromycin resistant Helicobacter pylori characterizes unidentified variants of multidrug resistant efflux pump genes", Gut Pathog, 6, pp.27~ (2014)
  88. Qureshi NN, "Evolution of amoxicillin resistance of Helicobacter pylori in vitro : characterization of resistance mechanisms", Microb Drug Resist, 20, pp.509~516 (2014)
  89. Binh TT, "Search for novel candidate mutations for metronidazole resistance in Helicobacter pylori using next-generation sequencing", Antimicrob Agents Chemother, 59, pp.2343~2348 (2015)
  90. Miftahussurur M, "Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal", BMC Microbiol, 16, pp.256~ (2016)
  91. Nezami BG, "Helicobacter pylori mutations detected by next-generation sequencing in formalin-fixed, paraffin-embedded gastric biopsy specimens are associated with treatment failure", J Clin Microbiol, 57, pp.e01834~18 (2019)
  92. Hulten KG, "Comparison of culture with antibiogram to nextgeneration sequencing using bacterial isolates and formalinfixed, paraffin-embedded gastric biopsies", Gastroenterology, 161, pp.1433~1442 (2021)
  93. Wenzhen Y, "Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials", Intern Med, 49, pp.1103~1109 (2010)
  94. Lee HJ, "Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance", J Infect Dis, 208, pp.1123~1130 (2013)
  95. Furuta T, "Pharmacogenomicsbased tailored versus standard therapeutic regimen for eradication of H. pylori", Clin Pharmacol Ther, 81, pp.521~528 (2007)
  96. Delchier JC, "Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection", Med Mal Infect, 50, pp.492~499 (2020)
  97. Hsieh MS, "Tailored susceptibilityguided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial", J Formos Med Assoc, 121, pp.1450~1457 (2022)
  98. Neri M, "Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments", Aliment Pharmacol Ther, 18, pp.821~827 (2003)
  99. Park CS, "Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance", Am J Gastroenterol, 109, pp.1595~1602 (2014)
  100. Martos M, "Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions", Eur J Gastroenterol Hepatol, 26, pp.1380~1384 (2014)
  101. Toracchio S, "Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication", Aliment Pharmacol Ther, 14, pp.1639~1643 (2000)
  102. Romano M, "Pretreatment antimicrobial-susceptibility testing in the eradication of H. pylori infection", Am J Gastroenterol, 95, pp.3317~3318 (2000)
  103. Romano M, "Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori", Clin Gastroenterol Hepatol, 1, pp.273~278 (2003)
  104. Ong S, "Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation : a multicenter randomized controlled trial", Helicobacter, 24, pp.e12654~ (2019)
  105. Choi YI, "Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients", World J Gastroenterol, 27, pp.5247~5258 (2021)
  106. Cha B, "Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area", Scand J Gastroenterol, 56, pp.1017~1022 (2021)
  107. Kim SJ, "A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations", Medicine(Baltimore), 101, pp.e30069~ (2022)
  108. Cho JH, "Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea : a randomized controlled trial", Expert Rev Anti Infect Ther, 20, pp.923~929 (2022)
  109. Marzio L, "Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole", Helicobacter, 11, pp.237~242 (2006)
  110. Zhou L, "Tailored versus triple plus bismuth or concomitant therapy as initial Helicobacter pylori treatment : a randomized trial", Helicobacter, 21, pp.91~99 (2016)
  111. Chen Q, "Randomised controlled trial : susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment", Aliment Pharmacol Ther, 49, pp.1385~1394 (2019)
  112. Pan J, "Is tailored therapy based on antibiotic susceptibility effective? A multicenter, open-label, randomized trial", Front Med, 14, pp.43~50 (2020)
  113. Li P, "Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients : a prospective clinical trial of first-line therapy", Front Microbiol, 13, pp.973975~ (2022)
  114. Gingold-Belfer R, "Susceptibility-guided versus empirical treatment for Helicobacter pylori infection : a systematic review and metaanalysis", J Gastroenterol Hepatol, 36, pp.2649~2658 (2021)
  115. Ouyang Y, "Susceptibilityguided therapy vs. bismuth-containing quadruple therapy as the first-line treatment for Helicobacter pylori infection: a systematic review and meta-analysis", Front Med(Lausanne), 9, pp.844915~ (2022)
  116. Nyssen OP, "Empirical vs. susceptibilityguided treatment of Helicobacter pylori infection : a systematic review and meta-analysis", Front Microbiol, 13, pp.913436~ (2022)
  117. Liou Jyh-Ming, "Treatment of Refractory Helicobacter pylori Infection-Tailored or Empirical Therapy", Gut and Liver, 16(1), pp.8~18 (2022), 거트앤리버 소화기연관학회협의회[DOI]
  118. Miwa H, "Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?", Aliment Pharmacol Ther, 17, pp.1545~1551 (2003)
  119. Lamouliatte H, "Second-line treatment for failure to eradicate Helicobacter pylori : a randomized trial comparing four treatment strategies", Aliment Pharmacol Ther, 18, pp.791~797 (2003)
  120. Breuer T, "Costs of diagnosis and treatment of Helicobacter pylori infection : when does choosing the treatment regimen based on susceptibility testing become cost effective?", Am J Gastroenterol, 94, pp.725~729 (1999)
  121. Tae-Geun Gweon, "An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment", Gut and Liver, 12(6), pp.648~654 (2018), 거트앤리버 소화기연관학회협의회
  122. Cho JH, "Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients", J Gastroenterol Hepatol, 34, pp.700~706 (2019)
  123. Choe AR, "Cost-effectiveness, efficacy, and safety analysis of tailored therapy in patients with Helicobacter pylori infection", J Clin Med, 10, pp.2619~ (2021)
  124. Chang YW, "Cost-effectiveness of empirical bismuth-based quadruple therapy and tailored therapy after clarithromycin resistance tests for Helicobacter pylori eradication", Dig Dis Sci, 67, pp.1222~1230 (2022)
  125. Suzuki S, "Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment : a multicentre randomised trial in Japan", Gut, 69, pp.1019~1026 (2020)
  126. Gotoda T, "Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan", J Gastroenterol, 55, pp.969~976 (2020)
  127. Furuta T, "Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori", Digestion, 101, pp.743~751 (2020)
  128. Ouyang Y, "Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication : a systematic review and meta-analysis", J Gastroenterol Hepatol, 37, pp.1666~1672 (2022)
  129. Chey WD, "Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe : randomized clinical trial", Gastroenterology, 163, pp.608~619 (2022)
  130. "Novel Drug Approvals for 2022" (2022)[URL]
  131. Sue Soichiro, "Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?", Gut and Liver, 15(6), pp.799~810 (2021), 거트앤리버 소화기연관학회협의회[DOI]
  132. Eto H, "Impact of body size on firstline Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy", Helicobacter, 26, pp.e12788~ (2021)
  133. Current European concepts in the management of Helicobacter pylori infection, "The Maastricht Consensus Report. European Helicobacter Pylori Study Group", Gut, 41, pp.8~13 (1997)

관련 논문AI추천

Treatment of Refractory Helicobacter pylori Infection-Tailored or Empirical TherapyLee Yi-Chia, Liou Jyh-Ming, Wu Ming-Shiang거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제1호Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from VietnamDang Thuy Ha, Duong Minh Thang, Ho Dang Quy Dung, Nguyen Quang Duat, Pham Hong Khanh, Tran Manh Hai, Tran Thanh Binh, Tran Thi Huyen Trang, Vu Van Khien, Yoshio Yamaoka거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제5호Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility of Helicobacter pylori Determined Using Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction김준성, 나수영, Choe Younghee, Kim Byung-Wook, Kim Min Ji거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제5호Antibiotic Resistance in Helicobacter pylori Strains and its Effect on H. pylori Eradication Rates in a Single Center in Korea박민, 김사현, 김종배, 김희정, 문병수, 안병락, 이규상, 이용찬, 임현철대한진단검사의학회 · Annals of Laboratory Medicine2013 · 제33권 제6호Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens오정환, 임철현거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제6호Bismuth-Based Quadruple Therapy versus Metronidazole- Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial양영주, Baik Gwang Ho, Bang Chang Seok, Jang Hyun Joo, Kae Sea Hyub, Kim Hak Yang, Kim Jinseob, Lee Sang Pyo, Lim Hyun, Seo Seung In, Shin Woon Geon거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제5호

이 간행물의 다른 논문 (18건)

Should All Undifferentiated Early Gastric Cancer Patients Undergoing Noncurative Endoscopic Resection Be Sent to the Operating Room?Kim Albert C., Kim Jung-Wookpp. 665-667Is Tegoprazan-Based Triple Therapy Effective in Regions with High Rates of Clarithromycin Resistance?최현호pp. 668-669Pretransplant Frailty on Postoperative Morbidity and Mortality after Liver Transplantation: Bystander or Upstander?Choi Won-Mookpp. 670-671Evaluating the Self-Expandable Metal Stents Placement in Malignant Biliary Obstruction: A Deeper DivePark Se Woo, Lee Kyong Joopp. 672-673Mesenchymal Stem Cell Therapy in Acute Liver FailureChen En-Qiang, Wang Yong-Hongpp. 674-683
원문 보기